PE20160125A1 - Pirazolpiridinas sustituidas - Google Patents
Pirazolpiridinas sustituidasInfo
- Publication number
- PE20160125A1 PE20160125A1 PE2016000029A PE2016000029A PE20160125A1 PE 20160125 A1 PE20160125 A1 PE 20160125A1 PE 2016000029 A PE2016000029 A PE 2016000029A PE 2016000029 A PE2016000029 A PE 2016000029A PE 20160125 A1 PE20160125 A1 PE 20160125A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- hydrogen
- pyrazolo
- pyrrolo
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de pirazolpiridina sustituidas que inhiben la quinasa MKNK1 y/o quinasa MKNK2 de formula general I, metodos para preparar dichos compuestos, compuestos intermediarios utiles para preparar dichos compuestos, composiciones farmaceuticas y combinaciones que comprenden a dichos compuestos para el tratamiento de un trastorno hiperproliferativo y/o de angiogenesis. Donde: Q-V es un grupo seleccionado de C (R1a)-N, N-C(R1a); A representa un compuesto de formula (i), etc; * indica el punto de union de dichos grupos al resto de la molecula. R1a es hidrogeno, etc; R1b es hidrogeno, etc; R1c es hidrogeno, etc; R2a es hidrogeno, etc; R2b es hidrogeno, etc. Son compuestos preferidos: [N-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazolo[3,4-b]piridin-5-amina]; [N-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazolo[3,4-c]piridin-5-amina].
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13175526 | 2013-07-08 | ||
EP13194902 | 2013-11-28 | ||
EP13195131 | 2013-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20160125A1 true PE20160125A1 (es) | 2016-03-17 |
Family
ID=51162789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000029A PE20160125A1 (es) | 2013-07-08 | 2014-07-04 | Pirazolpiridinas sustituidas |
Country Status (24)
Country | Link |
---|---|
US (1) | US20160159789A1 (es) |
EP (1) | EP3019505A1 (es) |
JP (1) | JP2016527216A (es) |
KR (1) | KR20160030239A (es) |
CN (1) | CN105531279A (es) |
AP (1) | AP2016009025A0 (es) |
AU (1) | AU2014289415A1 (es) |
CA (1) | CA2917380A1 (es) |
CL (1) | CL2016000038A1 (es) |
CR (1) | CR20160016A (es) |
CU (1) | CU20160003A7 (es) |
DO (1) | DOP2016000007A (es) |
EA (1) | EA201690183A1 (es) |
HK (1) | HK1223362A1 (es) |
IL (1) | IL243273A0 (es) |
MX (1) | MX2016000163A (es) |
NI (1) | NI201600006A (es) |
PE (1) | PE20160125A1 (es) |
PH (1) | PH12016500054A1 (es) |
SG (1) | SG11201510391VA (es) |
TN (1) | TN2016000005A1 (es) |
UY (1) | UY35651A (es) |
WO (1) | WO2015004024A1 (es) |
ZA (1) | ZA201600275B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201605867A (zh) * | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
CA2982984C (en) | 2015-04-20 | 2023-10-17 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
CA3050599A1 (en) * | 2017-01-20 | 2018-07-26 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridinpyrimidines |
EP3996710A1 (en) | 2019-07-10 | 2022-05-18 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations |
CN110483523B (zh) * | 2019-08-27 | 2022-11-22 | 药雅科技(上海)有限公司 | 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2280040T3 (es) * | 2003-07-24 | 2007-09-01 | Bayer Pharmaceuticals Corporation | Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos. |
WO2007076161A2 (en) * | 2005-12-27 | 2007-07-05 | Myriad Genetics, Inc | Compounds with therapeutic activity |
EP1889847A1 (en) * | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール[3,4−b]ピリジンRAF阻害剤 |
CN102712635A (zh) * | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | 用于抑制raf激酶的1h-吡唑并[3,4-b]吡啶化合物 |
CA2791114A1 (en) * | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
EP2776444A4 (en) * | 2011-11-10 | 2015-07-22 | Osi Pharmaceuticals Llc | dihydropteridinones |
-
2014
- 2014-07-04 AU AU2014289415A patent/AU2014289415A1/en not_active Abandoned
- 2014-07-04 EA EA201690183A patent/EA201690183A1/ru unknown
- 2014-07-04 TN TN2016000005A patent/TN2016000005A1/en unknown
- 2014-07-04 KR KR1020167003079A patent/KR20160030239A/ko not_active Application Discontinuation
- 2014-07-04 WO PCT/EP2014/064347 patent/WO2015004024A1/en active Application Filing
- 2014-07-04 EP EP14736772.6A patent/EP3019505A1/en not_active Withdrawn
- 2014-07-04 US US14/903,423 patent/US20160159789A1/en not_active Abandoned
- 2014-07-04 JP JP2016524760A patent/JP2016527216A/ja active Pending
- 2014-07-04 AP AP2016009025A patent/AP2016009025A0/en unknown
- 2014-07-04 PE PE2016000029A patent/PE20160125A1/es not_active Application Discontinuation
- 2014-07-04 CA CA2917380A patent/CA2917380A1/en not_active Abandoned
- 2014-07-04 MX MX2016000163A patent/MX2016000163A/es unknown
- 2014-07-04 CN CN201480049419.4A patent/CN105531279A/zh active Pending
- 2014-07-04 SG SG11201510391VA patent/SG11201510391VA/en unknown
- 2014-07-08 UY UY35651A patent/UY35651A/es not_active Application Discontinuation
-
2015
- 2015-12-21 IL IL243273A patent/IL243273A0/en unknown
-
2016
- 2016-01-07 PH PH12016500054A patent/PH12016500054A1/en unknown
- 2016-01-08 NI NI201600006A patent/NI201600006A/es unknown
- 2016-01-08 CU CUP2016000003A patent/CU20160003A7/es unknown
- 2016-01-08 CR CR20160016A patent/CR20160016A/es unknown
- 2016-01-08 DO DO2016000007A patent/DOP2016000007A/es unknown
- 2016-01-08 CL CL2016000038A patent/CL2016000038A1/es unknown
- 2016-01-13 ZA ZA2016/00275A patent/ZA201600275B/en unknown
- 2016-10-05 HK HK16111573.4A patent/HK1223362A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EA201690183A1 (ru) | 2016-06-30 |
NI201600006A (es) | 2016-02-12 |
DOP2016000007A (es) | 2016-02-15 |
MX2016000163A (es) | 2016-04-15 |
JP2016527216A (ja) | 2016-09-08 |
EP3019505A1 (en) | 2016-05-18 |
HK1223362A1 (zh) | 2017-07-28 |
UY35651A (es) | 2015-02-27 |
IL243273A0 (en) | 2016-02-29 |
TN2016000005A1 (en) | 2017-07-05 |
CA2917380A1 (en) | 2015-01-15 |
AP2016009025A0 (en) | 2016-02-29 |
KR20160030239A (ko) | 2016-03-16 |
CU20160003A7 (es) | 2017-02-02 |
CL2016000038A1 (es) | 2016-07-29 |
US20160159789A1 (en) | 2016-06-09 |
AU2014289415A1 (en) | 2016-01-21 |
ZA201600275B (en) | 2019-04-24 |
CN105531279A (zh) | 2016-04-27 |
WO2015004024A1 (en) | 2015-01-15 |
CR20160016A (es) | 2016-03-04 |
PH12016500054A1 (en) | 2016-04-04 |
SG11201510391VA (en) | 2016-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20160125A1 (es) | Pirazolpiridinas sustituidas | |
UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
RS54840B1 (sr) | 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido(2,3-d)pirimidin-6-il)fenil)urea kao inhibitor raf kinaze za tretman kancera | |
UY39887A (es) | (r)-(2-cloro-3-(trifluorometil)fenil)(1-(5-fluoropirimidin2-il)-4-metil-6,7-dihidro-1h-[1,2,3]triazolo-[4,5-c]piridin5(4h)-il)metanona como modulador del receptor p2x7 | |
CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
PE20151776A1 (es) | Compuestos de heteroarilo y sus usos | |
CO6531451A2 (es) | Compuesto de pirrolo[2,3-d]pirimidina | |
ECSP12011691A (es) | Compuestos de urea que contienen heteroarilo 5,6-bicíclicos como inhibidores de quinasa | |
UY34870A (es) | Cristales de sal | |
ECSP13012703A (es) | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak | |
DOP2014000055A (es) | Derivados de pirrolopirimidina y purina | |
EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
EA201890061A3 (ru) | Производные пиразоло[1,5-a]пиридина и способы их применения | |
UA115354C2 (uk) | ПОХІДНІ ОКТАГІДРОПІРОЛО[3,4-c]ПІРОЛУ ТА ЇХ АНАЛОГИ ЯК ІНГІБІТОРИ АУТОТАКСИНУ | |
CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CO6602133A2 (es) | Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas | |
CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
BR112012019511A2 (pt) | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. | |
PH12016501699A1 (en) | 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
SV2017005368A (es) | [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
EA201690716A1 (ru) | ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ | |
MX2020001628A (es) | Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona. | |
PE20190778A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |